

**Jean-Paul H. PRIEELS**

**Education:**

1975: *Ph.D. in Biochemistry at the Free University of Brussels (ULB) - Belgium*

**Career:**

1975 – 1976 : *Research Associate ULB*

1976 – 1977 : *Research Associate ICP/UCL*

1977 – 1978 : *Research Associate Duke University Medical School*

1978 – 1981 : *Assistant ULB*

1981 – 1983 : *Supervisor ULB*

1983 – 1987 : *Biotechnology Manager Petrofina*

1987 – 1988 : *Associate Director,  
R&D Projects Evaluation and Co-ordination SmithKline  
Beecham Biologicals now GlaxoSmithKline Vaccines*

1988 – 1990 : *Director,  
R&D Projects Evaluation and Co-ordination*

1990 – 1991 : *Director, R&D Projects Evaluation  
and Protein Purification*

1991 – 1992 : *Director R&D Technical Assessment,  
Recovery Process and Vaccine Formulation Sciences*

1993 – 1997 : *Director,  
Vaccine Technologies and Extramural R&D*

1997 – 1998 : *Vice President  
Vaccine Technologies and Extramural R&D*

04/98 – 08/99 : *Vice President ,  
Research & Pre-clinical Development*

From 09/1999 : *Vice President,  
Research & Development  
Member of management committee and  
Member of the Board GSK Biologicals*

2006 -01/2011: *Senior Vice President Research and Development*

February 2011- July 2015 *Advisor @ GSK Vaccine R&D*

*Member of SAB @ Singapore Bioprocessing Technology Institut 2007-2015 Chairman of  
SAB @ Singapore Bioprocessing Technology Institute 2016-2018*

*Member SAB @Infectious Disease Research Institute (Seattle) 03/2011-03/ 2015*

<i>Member of SAB CureVac (Germany)</i>	2015-
<i>Member of SAB Imcyse</i>	2015-
<i>Non executive director @ Pevion AG (Bern)</i>	2011- 2013
<i>Non executive director @ Okairos AG(Basel)</i>	2011- 2013
<i>Co-Founder &amp; CEO Masthercell (Gosselies)</i>	11/ 2011 to 4/ 2014
<i>Member of the Board @ Masthercell</i>	09/2017-
<i>Non executive director @ Vaximm AG(Mannheim)</i>	January 2012-
<i>Non executive director @ Theradiag SA (Paris)</i>	06/ 2012- 06/2016
<i>Member of SAB @ MolMed SpA(Milano)</i>	2012-2016
<i>Member of European Vaccine Initiative Board of Stakeholders</i>	May 2013-
<i>Non executive director Abivax SA (Paris)</i>	12/ 2013-7/2017
<i>Member of SAB@Abivax SA (Paris)</i>	12/2013-
<i>Board Member @ Q-Biologicals SA (Ghent)</i>	March 2014-2017
<i>Board Member @ DNALytics SA (Belgium)</i>	Sept 2014-
<i>Non-executive director @ Bone Therapeutics</i>	March 2015-
<i>Non-executive director @ Promethera Biosciences</i>	2015-Sept. 2017
<i>Non-executive director @ NCardia</i>	May 2015-
<i>Non-executive director @ Themis (Austria)</i>	May 2015-
<i>Non-executive director @ Leukocare (Germany)</i>	June 2015-
<i>Non-executive director @ Nouscom (Switzerland)</i>	June 2015-
<i>Non executive director @ Ogeda (Belgium)</i>	10/ 2015-04/2017
<i>Non-executive director @ PDC line Pharma</i>	September 2016-
<i>Cofounder &amp; Board Member @ Paracrine Biologicals</i>	May 2019-

## **Publications**

Jean-Paul Prieels, Patrick Stragier, François Lesage, Didier Argentin, Alex Bollen

*Mastering Industrialization of cell therapy products*  
Bioprocess International, 2012, Vol 10, s3, 12-15

Steven G. Reed, Rhea N. Coler, Wilfried Dalemans, Esterlina V. Tan, Eduardo C. DeLa Cruz, Randall J. Basaraba, Ian M. Orme, Yasir A. W. Skeiky, Mark R. Alderson, Karen D. Cowgill, Jean-Paul Prieels, Rodolfo M. Abalos, Marie-Claude Dubois, Joe Cohen, Pascal Mettens, and Yves Lobet

*Defined tuberculosis vaccine, Mtb72F/AS02A, evidence of protection in cynomolgus monkeys*  
PNAS, 2009 Feb 17; 106 (7), 2301-6

Prymula R, Peeters P, Chrobok V, Kriz P, Novakova E, Kaliskova E, Kohl I, Lommel P, Poolman J, Prieels JP, Schuerman L.

*Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study.*  
Lancet. 2006 Mar 4;367(9512):740-8.

Robert Putnak J, Collier BA, Voss G, Vaughn DW, Clements D, Peters I, Bignami G, Houg HS, Chen RC, Barvir DA, Seriwatana J, Cayphas S, Garçon N, Gheysen D, Kanesa-Thanan N, McDonnell M, Humphreys T, Eckels KH, Prieels JP, Innis BL.

*An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model.*  
Vaccine. 2005 Aug 15;23(35):4442-52.

Purcell RH, Nguyen H, Shapiro M, Engle RE, Govindarajan S, Blackwelder WC, Wong DC, Prieels JP, Emerson SU.

*Pre-clinical immunogenicity and efficacy trial of a recombinant hepatitis E vaccine.*  
Vaccine. 2003 Jun 2;21(19-20):2607-15.

Prince GA, Denamur F, Deschamps M, Garçon N, Prieels JP, Slaoui M, Thiriart C, Porter DD. Monophosphoryl lipid A adjuvant reverses a principal histologic parameter of formalin-inactivated respiratory syncytial virus vaccine-induced disease.  
Vaccine. 2001 Feb 28;19(15-16):2048-54.

Prince GA, Capiou C, Deschamps M, Fabry L, Garçon N, Gheysen D, Prieels JP, Thiry G, Van Opstal O, Porter DD.  
Efficacy and safety studies of a recombinant chimeric respiratory syncytial virus FG glycoprotein vaccine in cotton rats.  
J Virol. 2000 Nov;74(22):10287-92.

Prince GA, Prieels JP, Slaoui M, Porter DD.  
*Pulmonary lesions in primary respiratory syncytial virus infection, reinfection, and vaccine-enhanced disease in the cotton rat (Sigmodon hispidus).*  
Lab Invest. 1999 Nov;79(11):1385-92.

Stoute JA, Slaoui M, Heppner DG, Garçon N, Kester KE, Desmons P, Schwenk R, Van Hardenhove M, Welde BT, Marchand M, Hall BT, Ockenhouse CF, Mormin P, White K, Magill A, Voet P, Golenda C, Glenn GM, Biernaux S, Krzych U, Prieels JP, Sadoff JC, Ballou WR, Cohen JC

*A preliminary evaluation of a recombinant circumsporozoite protein malaria vaccine against Plasmodium falciparum.*  
N Engl J Med, 1997 336: 86-91.

Neuzil KM, Johnson JE, Tang YW, Prieels JP, Slaoui M, Garçon N, Graham BS.  
*Adjuvants influence the quantitative and qualitative immune response in BALB/c mice immunized with respiratory syncytial virus FG subunit vaccine.*  
Vaccine. 1997 Apr;15(5):525-32.

Moguilevsky N, Steens M, Thiriart C, Prieels JP, Thiry L, Bollen A.  
*Lethal oxidative damage to human immunodeficiency virus by human recombinant myeloperoxidase.*  
FEBS Lett. 1992 May 18;302(3):209-12.

Mbuyi-Kalala A, Perraudin JP, Prieels JP.  
*Anomerization and hydrolysis of lactose by beta-galactosidase from Saccharomyces lactis.*  
Arch Biochem Biophys. 1990 Mar;277(2):434-8.

Regoeczi E, Chindemi PA, Debanne MT, Prieels JP.  
Lactoferrin catabolism in the rat liver.  
Am J Physiol. 1985 Jan;248(1 Pt 1):G8-14.

Delforge A, Stryckmans P, Prieels JP, Bieva C, Ronge-Collard E, Schlusberg J, Eflora A.  
*Lactoferrin: its role as a regulator of human granulopoiesis?*

Ann N Y Acad Sci. 1985;459:85-96.

Burger MM, Finne J, Prieels JP.  
*Mutants, revertants and variants of metastasis.*  
Biochem Soc Trans. 1984 Jun;12(3):553-6.

Stryckmans P, Delforge A, Amson RB, Prieels JP, Telerman A, Bieva C, Deschuyteneer M, Ronge-Collard E.

*Lactoferrin: no evidence for its role in regulation of CSA production by human lymphocytes and monocytes.*  
Blood Cells. 1984;10(2-3):369-95.

Deschuyteneer M, Prieels JP, Mosselmans R.  
*Galactose-specific adsorptive endocytosis: an ultrastructural qualitative and quantitative study in cultured rat hepatocytes.*  
Biol Cell. 1984;50(1):17-29.

Rauvala H, Prieels JP, Finne J.  
*Cell adhesion mediated by a purified fucosyltransferase.*  
Proc Natl Acad Sci U S A. 1983 Jul;80(13):3991-5.

Perraudin JP, Guillard R, Prieels JP, Torchia T, Dubois T.  
*Disulfide content of reduced hen egg white and human milk lysozymes during the folding process.*  
FEBS Lett. 1983 Mar 21;153(2):349-52.

Prieels JP, Monnom D, Perraudin JP, Finne J, Burger M.  
*Enzymic properties of an N-acetylglucosaminide 3-alpha-L-fucosyltransferase of a wheat-germ agglutinin-resistant melanoma clone.*  
Eur J Biochem. 1983 Feb 1;130(2):347-51.

Dubois T, Guillard R, Prieels JP, Perraudin JP.  
*Comparison between the folding of reduced hen egg white lysozyme and that of reduced human milk lysozyme.*  
Biochemistry. 1982 Dec 7;21(25):6516-23.

Perraudin JP, Prieels JP.  
*Lactoferrin binding to lysozyme-treated Micrococcus luteus.*  
Biochim Biophys Acta. 1982 Sep 17;718(1):42-8.

Burger MM, Tao TW, Finne J, Prieels JP.  
*The influence of membrane mutations on metastasis.*  
Biosci Rep. 1982 Aug;2(8):597-9.

Finne J, Burger MM, Prieels JP.  
*Enzymatic basis for a lectin-resistant phenotype: increase in a fucosyltransferase in mouse melanoma cells.*  
J Cell Biol. 1982 Feb;92(2):277-82.

Sadler JE, Beyer TA, Oppenheimer CL, Paulson JC, Prieels JP, Rearick JI, Hill RL.  
*Purification of mammalian glycosyltransferases.*  
Methods Enzymol. 1982;83:458-514.

Prieels JP, Monnom D, Dolmans M, Beyer TA, Hill RL.  
*Co-purification of the Lewis blood group N-acetylglucosaminide alpha 1 goes to 4 fucosyltransferase and an N-acetylglucosaminide alpha 1 goes to 3 fucosyltransferase from human milk.*  
J Biol Chem. 1981 Oct 25;256(20):10456-63.

- Perraudin JP, Prieels JP.  
*Agglutinability of Micrococcus luteus by human lactoferrin upon lysozyme Arch Int Physiol Biochim.* 1980 Feb;88(1):B43-B44.
- Abernethy JL, De Preter J, Prieels JP.  
*Evidence for an internal homology in human lactoferrin structure*  
Arch Int Physiol Biochim. 1980 Feb;88(1):B12-B13.
- Wanson JC, Bernaert D, May C, Deschuyteneer M, Prieels JP.  
*Isolation and culture of adult rat hepatocytes and preneoplastic nodules from diethylnitrosamine treated livers: glucose-6-phosphatase distribution, albumin synthesis and hepatic binding protein activity.*  
Ann N Y Acad Sci. 1980;349:413-5.
- Hill RL, Pizzo SV, Imber M, Lehrman M, Prieels JP, Glasgow LR, Guthrow CE, Paulson JC.  
*Receptors on hepatocytes that bind ligands containing fucosyl alpha 1,3 N-acetylglucosamine linkages.*  
Birth Defects Orig Artic Ser. 1980;16(1):85-91
- Beyer TA, Rearick JI, Paulson JC, Prieels JP, Sadler JE, Hill RL.  
*Biosynthesis of mammalian glycoproteins. Glycosylation pathways in the synthesis of the nonreducing terminal sequences.*  
J Biol Chem. 1979 Dec 25;254(24):12531-4.
- Deschuyteneer M, Prieels JP, May C, Wanson JC.  
*Presence of the asialoglycoproteins-binding protein in primary monolayer culture of adult rat hepatocytes [proceedings]*  
Arch Int Physiol Biochim. 1979 Oct;87(4):804-5
- Prieels JP, Bell JE, Schindler M, Castellino FJ, Hill RL.  
*Involvement of histidine-32 in the biological activity of alpha-lactalbumin.*  
Biochemistry. 1979 May 1;18(9):1771-6
- Paulson JC, Prieels JP, Glasgow LR, Hill RL.  
*Sialyl- and fucosyltransferases in the biosynthesis of asparaginyl-linked oligosaccharides in glycoproteins. Mutually exclusive glycosylation by beta-galactoside alpha2 goes to 6 sialyltransferase and N-acetylglucosaminide alpha1 goes to 3 fucosyltransferase.*  
J Biol Chem. 1978 Aug 25;253(16):5617-24
- Prieels JP, Pizzo SV, Glasgow LR, Paulson JC, Hill RL.  
*Hepatic receptor that specifically binds oligosaccharides containing fucosyl alpha1 leads to 3 N-acetylglucosamine linkages.*  
Proc Natl Acad Sci U S A. 1978 May;75(5):2215-9
- Danhaive P, de Vries-Petiau GM, Prieels JP, Dolmans M, Leonis J.  
*Properties of galactosyltransferase from human milk fat globules]*  
Arch Int Physiol Biochim. 1977 Dec;85(5):960-1
- Prieels JP, Schluselberg J.  
*Heterogeneity in alpha-lactalbumins. I. Human alpha-lactalbumin.*  
Biochim Biophys Acta. 1977 Mar 28;491(1):76-81.
- Prieels JP, Beyers T, Hill RL.  
*Human milk]*  
Biochem Soc Trans. 1977;5(4):838-9]
- Prieels JP, Dolmans M, Schindler M, Sharon N.  
*The binding of glycoconjugates to human-milk D-galactosyltransferase.*

Eur J Biochem. 1976 Jul 15;66(3):579-82.

Maes E, Prieels JP, Dolmans M, Leonis J.  
*Identification of two genetic variants of goat alpha-lactalbumin.*  
Arch Int Physiol Biochim. 1976;84(3):641-2.]

Prieels JP, Maes E, Dolmans M, Leonis J.  
*Heterogeneity of human milk beta(1-4)-D-galactosyltransferase.*  
Eur J Biochem. 1975 Dec 15;60(2):525-31.

Prieels JP, Dolmans M, Leonis J, Brew K.  
*Nitration of tyrosyl residues in human alpha-lactalbumin. Effect on lactose synthase specifier activity.*  
Eur J Biochem. 1975 Dec 15;60(2):533-9.

Prieels JP, Barel AO.  
*A fluorimetric study of the interactions of insolubilized human alpha-lactalbumin with galactosyl transferase (A-protein) and with anti-alpha-lactalbumin antibodies.*  
Biochim Biophys Acta. 1975 Jun 26;393(2):496-504.

Prieels JP, Poortmans J, Dolmans M, Leonis J.  
*Immunological cross-reactions of alpha-lactalbumins from different species.*  
Eur J Biochem. 1975 Jan 15;50(3):523-7.

Barel AO, Prieels JP.  
*Fluorimetric study of conformational changes of various alpha-lactalbumins on agarose carriers.*  
Eur J Biochem. 1975 Jan 2;50(2):463-73.

Schlüsselberg J, Noyer M, Prieels JP.  
*Chromatographic equilibrium of human alpha-lactalbumin.*  
Arch Int Physiol Biochim. 1974 Dec;82(5):1013-4

Prieels JP, Dolmans M, Leonis J, Brew K.  
*Modification of tyrosine residues in human alpha-lactalbumin: effect upon the lactose-synthase specifier activity.*  
Arch Int Physiol Biochim. 1974 Dec;82(5):1003-5.

Perraudin JP, Prieels JP, Leonis J.  
*Interaction between lysozyme and some lactoferrin complex in human milk.*  
Arch Int Physiol Biochim. 1974 Dec;82(5):1001

Prieels JP, Cludts M, Dolmans M, Leonis J.  
*The isolation of glyco-alpha-lactalbumins from some ruminant milks.*  
Arch Int Physiol Biochim. 1974 Feb;82(1):194.

Barel AO, Prieels JP, Maes E, Looze Y, Leonis J.  
*Comparative physicochemical studies of human alpha-lactalbumin and human lysozyme.*  
Biochim Biophys Acta. 1972 Feb 29;257(2):288-96]